natgillin/translations-raw huggingface dataset:
The summaries of opinion of the Committee for Orphan Medicinal Products for Sprycel can be found on the Agency’s website ema.europa.eu/Find medicine/Human medicines/Rare disease designation:
Harvikravimite komitee arvamuse kokkuvõtted Spryceli kohta on ameti veebilehel ema.europa.eu/Find medicine/Human medicines/Rare disease designation:
The summaries of opinion of the Committee for Orphan Medicinal Products for Tracleer can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (PAH), and ema.europa.eu/Find medicine/Human medicines/Rare disease designation (systemic sclerosis).
Harvikravimite komitee arvamuse kokkuvõte Tracleeri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (pulmonaalne arteriaalne hüpertensioon) ja ema.europa.eu/Find medicine/Human medicines/Rare disease designation (süsteemne skleroos).
The summaries of the opinion of the Committee for Orphan Medicinal Products for Gazyvaro can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (CLL and FL).
Harvikravimite komitee arvamuse kokkuvõte Gazyvaro kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (krooniline lümfotsütaarne leukeemia ja follulaarne lümfoom).
The summaries of the opinion of the Committee for Orphan Medicinal Products for Iclusig can be found on the Agency’s website:
Harvikravimite komitee arvamuse kokkuvõte Iclusigi kohta on ameti veebilehel:
The summaries of the opinion of the Committee for Orphan Medicinal Products for Lenvima can be found on the Agency’s website:
Harvikravimite komitee arvamuse kokkuvõte Lenvima kohta on ameti veebilehel:
The summaries of the opinion of the Committee for Orphan Medicinal Products for Vidaza can be found on the Agency’s website: here (myelodysplastic syndromes) and here (AML).
Harvikravimite komitee arvamuse kokkuvõte Vidaza kohta on ameti veebilehel: siin (müelodüsplastilised sündroomid) ja siin (äge müeloidleukeemia).
The summaries of the opinions of the Committee for Orphan Medicinal Products for Ravicti can be found on the Agency’s website:
Harvikravimite komitee arvamuste kokkuvõtted Ravicti kohta on ameti veebilehel:
The summaries of the opinions of the Committee for Orphan Medicinal Products for Revlimid can be found on the Agency’s website ema.europa.eu/Find medicine/Human medicines/Rare disease designations:
Harvikravimite komitee arvamuste kokkuvõtted Revlimidi kohta on ameti veebilehel aadressil ema.europa.eu/Find medicine/Human medicines/Rare disease designations:
The summaries of the opinions of the Committee for Orphan Medicinal Products for Signifor can be found on the Agency’s website:
Harvikravimite komitee arvamuste kokkuvõtted Signifori kohta on ameti veebilehel:
The summaries of the opinions of the Committee for Orphan Medicinal Products for Zavesca on the Agency’s website ema.europa.eu/Find medicine/Human medicines/Rare disease designations:
Harvikravimite komitee arvamuste kokkuvõtted Zavesca kohta on ameti veebilehel aadressil ema.europa.eu/Find medicine/Human medicines/Rare disease designations:
The summary of opinion of the Committee for Orphan Medicinal Products for Ceplene can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Ceplene kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of opinion of the Committee for Orphan Medicinal Products for Evoltra can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare Disease Designations.
Harvikravimite komitee arvamuse kokkuvõte Evoltra kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare Disease Designations.
The summary of opinion of the Committee for Orphan Medicinal Products for Exjade can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Exjade kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of opinion of the Committee for Orphan Medicinal Products for Inovelon can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Inoveloni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
The summary of opinion of the Committee for Orphan Medicinal Products for Kuvan can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Kuvani kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
The summary of opinion of the Committee for Orphan Medicinal Products for Lysodren can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Lysodreni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of opinion of the Committee for Orphan Medicinal Products for Mozobil is available here.
Harvikravimite komitee arvamuse kokkuvõtte Mozobili kohta leiate siit.
The summary of opinion of the Committee for Orphan Medicinal Products for Peyona can be found on the Agency’s website ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Peyona kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of opinion of the Committee for Orphan Medicinal Products for Tasigna can be found on the Agency’s website ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Tasigna kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The Summary of Product Characteristics
Ravimi omaduste kokkuvõte
The Summary of Product Characteristics
Ravimi omaduste kokkuvõte.
The Summary of Product Characteristics
ravimi omaduste kokkuvõte;
The Summary of Product Characteristics
Ravimi omaduste kokkuvõtet
The Summary of Product Characteristics
ravimi omaduste kokkuvõtet tervishoiutöötajate koolitusmaterjali
The Summary of Product Characteristics
ravimi omaduste kokkuvõtet,
The Summary of Product Characteristics
ravimi omaduste kokkuvõtet;
The Summary of Product Characteristics
toote omaduste kokkuvõte tervishoiutöötajate koolitusmaterjal
The Summary of Product Characteristics (SmPC)
ravimi omaduste kokkuvõte;
The Summary of Product Characteristics (SmPC) of MabThera100 mg and 500 mg concentrate for solution for infusion should be referred to for information on dosing instructions and method of administration.
Teave annustamisjuhiste ja manustamisviisi kohta vt MabThera 100 mg ja 500 mg infusioonilahuse kontsentraadi ravimi omaduste kokkuvõte.
The summary of product characteristics and package leaflet of bimatoprost (formulations 0.01%) should be amended to reflect the following adverse drug reactions: iris hyperpigmentation with a frequency uncommon and macular oedema, blepharal pigmentation, periorbital and lid changes including deepening of the eyelid sulcus and dry eye with a frequency not known.
Bimatoprosti (0,01% ravimvorm) ravimi omaduste kokkuvõtet ja pakendi infolehte tuleb muuta, et lisada neisse järgmised kõrvaltoimed: vikerkesta hüperpigmentatsioon, mille esinemissagedus on haruldane, maakula ödeem, silmalau pigmentatsioon, periorbitaalsed ja silmalau muutused, sh silmalau vao süvenemine ja silmade kuivus, mille esinemissagedus on teadmata.
The summary of product characteristics and the patient information leaflet.
Ravimi omaduste kokkuvõte ja patsiendi infoleht.
The Summary of Product Characteristics for Opsumit;
Opsumiti ravimi omaduste kokkuvõtet;
The Summary of Product Characteristics for peginterferon alfa and ribavirin must therefore be consulted before starting therapy with INCIVO.
Seetõttu tuleb enne ravi alustamist INCIVO’ga tutvuda alfapeginterferooni ja ribaviriini ravimi omaduste kokkuvõtetega.
The Summary of Product Characteristics for the co-administered ritonavir-boosted protease inhibitor should be consulted.
Tuleb tutvuda koosmanustatava ritonaviiriga võimendatud proteaasi inhibiitori ravimi omaduste kokkuvõttega.
The Summary of Product Characteristics for Uptravi;
Uptravi ravimi omaduste kokkuvõte;
The Summary of Product Characteristics of cobicistat or ritonavir as appropriate, must therefore be consulted prior to initiation of therapy with PREZISTA.
Enne ravi alustamist PREZISTA’ga tuleb seega vajaduse korral lugeda kobitsüstaadi ja ritonaviiri ravimi omaduste kokkuvõtet.
The Summary of Product Characteristics of cobicistat or ritonavir as appropriate, must therefore be consulted prior to initiation of therapy with PREZISTA.
Enne ravi alustamist PREZISTA’ga tuleb vajaduse korral lugeda kobitsüstaadi ja ritonaviiri ravimi omaduste kokkuvõtet.
The Summary of Product Characteristics of cobicistat or ritonavir as appropriate, must therefore be consulted prior to initiation of therapy with PREZISTA.
Seetõttu tuleb enne PREZISTA-ravi alustamist tutvuda vastavalt kas kobitsüstaadi või ritonaviiri ravimi omaduste kokkuvõttega.
The Summary of Product Characteristics of peginterferon alfa and ribavirin (PR) must be consulted prior to initiation of therapy with Victrelis.
Enne Victrelise ravi alustamist tuleb tutvuda alfapeginterferooni ja ribaviriini (peginterferon alfa and ribavirin, PR) ravimi omaduste kokkuvõtetega.
The Summary of Product Characteristics of ritonavir must therefore be consulted prior to initiation of therapy with Aptivus (especially as regards the contraindications, warnings and undesirable effects sections).
Seega tuleb enne Aptivus’e ravi alustamist hoolikalt uurida ritonaviiri Ravimi omaduste kokkuvõtet (eelkõige lõike, mis puudutavad vastunäidustusi, hoiatusi ja kahjulikke kõrvaltoimeid).
The Summary of Product Characteristics of the co-administered protease inhibitor should be consulted for specific recommendations.
Täpsemate annustamisjuhiste saamiseks tutvuge samaaegselt manustatava proteaasi inhibiitori ravimi omaduste kokkuvõttega (SPC).
The Summary of Product Characteristics;
Ravimi omaduste kokkuvõte;
The summary of the opinion of the Committee for Orphan Medicinal Products for Adcetris can be found on the Agency’s website:
Harvikravimite komitee arvamuse kokkuvõte Adcetrise kohta on ameti veebilehel:
The summary of the opinion of the Committee for Orphan Medicinal Products for Adempas can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Adempase kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Alprolix can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Alprolixi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Arzerra can also be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Arzerra kohta on samuti ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
The summary of the opinion of the Committee for Orphan Medicinal Products for Atriance can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Atriance kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Blincyto can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Blincyto kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Bosulif can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Bosulifi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Bronchitol can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Bronchitoli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
The summary of the opinion of the Committee for Orphan Medicinal Products for Cayston can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Caystoni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Cerdelga can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Cerdelga kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Coagadex can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Coagadexi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Cometriq can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Cometriqi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Cresemba can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (invasive aspergillosis) ema.europa.eu/Find medicine/Human medicines/Rare disease designation (mucormycosis)
Harvikravimite komitee arvamuse kokkuvõte Cresemba kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation (invasiivne aspergilloos) ema.europa.eu/Find medicine/Human medicines/Rare disease designation (mukormükoos)
The summary of the opinion of the Committee for Orphan Medicinal Products for Dacogen can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Dacogeni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Darzalex can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Darzalexi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Defitelio can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Defitelio kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Deltyba can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Deltyba kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Diacomit can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Diacomiti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
The summary of the opinion of the Committee for Orphan Medicinal Products for Elaprase can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Elaprase kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Elocta can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Elocta kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Esbriet can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Esbrieti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
The summary of the opinion of the Committee for Orphan Medicinal Products for Farydak can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Farydaki kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Firazyr can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Firazyri kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
The summary of the opinion of the Committee for Orphan Medicinal Products for Firdapse can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Firdapse kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Galafold can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Galafoldi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Glybera can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Glybera kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Granupas can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Granupase kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Hetlioz can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Hetliozi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Holoclar can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Holoclari kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Idelvion can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Idelvioni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Imnovid can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Imnovidi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Increlex can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Increlexi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Kalydeco can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Kalydeco kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Kanuma can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Kanuma kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Ketoconazole HRA can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Ketoconazole HRA kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Kolbam can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Kolbami kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Kyprolis can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Kyprolise kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Lartruvo can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Lartruvo kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Lynparza can be found on the Agency’s website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Harvikravimite komitee arvamuse kokkuvõte Lynparza kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
The summary of the opinion of the Committee for Orphan Medicinal Products for Myozyme can be found on the Agency’s website ema.europa.eu/Find medicine/Human medicines/Rare disease designations.
Harvikravimite komitee arvamuse kokkuvõte Myozyme kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designations.